New partners for Phase 2 trial of next-gen lithium therapy AL001
Alzamend Neuro is partnering with Mass General Hospital for a Phase 2 trial of AL001, a next-generation lithium drug for Alzheimer’s dementia.| Alzheimer's News Today
Alzamend Neuro is partnering with Mass General Hospital for a Phase 2 trial of AL001, a next-generation lithium drug for Alzheimer’s dementia.| Alzheimer's News Today
As columnist Ray Burow watched her mother's dementia progress, she often returned to a friend's wise words about coping with loss.| Alzheimer's News Today
A reader's comment prompts columnist Ray Burow to reinforce the purpose of her column: providing hope to those with an Alzheimer's diagnosis.| Alzheimer's News Today
Nearly half of some 200 mild-to-moderate Alzheimer’s patients treated with oral simufilam for one year showed gains in cognitive tests.| Alzheimer's News Today
Columnist Ray Burow now understands that those who get an Alzheimer's diagnosis need time to come to grips with the disease.| Alzheimer's News Today
Early menopause and poor brain-connection health may interact to increase Alzheimer's disease risk in women, a study found.| Alzheimer's News Today
Columnist Ray Burow, grieving the loss of her dear friend Richard Allen Farmer, reflects on how he cared for her mother, who had Alzheimer's.| Alzheimer's News Today
Experts in Alzheimer’s and dementia care explain the challenges of getting an early and accurate diagnosis and what can be done to solve it.| Alzheimer's News Today
Columnist Ray Burow offers factors to consider when discussing whether nursing home care or at-home care is better for your loved one.| Alzheimer's News Today
Columnist Ray Burow explains how her mother's Alzheimer's called to mind Dickens' quote about the "spring of hope" and "winter of despair."| Alzheimer's News Today
Category archive page for Columns.| Alzheimer's News Today
Experimental blarcamesine (Anavex 2-73) was able to slow cognitive and functional decline in early Alzheimer’s patients over a year, data show.| Alzheimer's News Today
Zunveyl, a new oral mild-to-moderate Alzheimer's therapy, showed bioequivalence to galanotamine but fewer GI issues like nausea in studies.| Alzheimer's News Today
The FDA granted regenerative medicine advanced therapy (RMAT) status to experimental cell therapy Lomecel-B for mild Alzheimer’s disease.| Alzheimer's News Today
An advisory committee to the U.S. Food and Drug Administration (FDA) unanimously voted in favor of donanemab for early Alzheimer's.| Alzheimer's News Today
Buntanetap, a small molecule from Annovis Bio, improved cognitive function in people with mild Alzheimer’s with certain biomarkers.| Alzheimer's News Today
A total of 1,929 Alzheimer's patients have enrolled in two simufilam studies, which the FDA said could support its application for approval.| Alzheimer's News Today
